Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492350 | 0.95 | CRHR1 (0.44) | CRHR1CNR2 | |
| SCHEMBL5497565 | 0.88 | CRHR1 (0.38) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL5492499 | 0.81 | CRHR1 (0.47) | CRHR1CNR2DRD2HTR7HTR6 | |
| SCHEMBL5495330 | 0.81 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL5493011 | 0.80 | CRHR1 (0.47) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL5495271 | 0.78 | CRHR1 (0.47) | CRHR1HTTSMN1; SMN2 | |
| SCHEMBL5488989 | 0.77 | CRHR1 (0.46) | CRHR1CNR2CNR1 | |
| SCHEMBL5493199 | 0.77 | CRHR1 (0.45) | CRHR1CNR2DRD2HTR7HTR6 | |
| SCHEMBL5495267 | 0.74 | CRHR1 (0.45) | CRHR1CNR2DRD2HTR7HTR6 | |
| SCHEMBL2193222 | 0.74 | CRHR1 (0.49) | CRHR1DRD2HTR1AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | claimed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CRHR1 2/4885CNR2 125/4885DRD2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.